Table 3.
Clinical activity assessments in the multi dose phase at eight weeks
| Placebo | MTRX1011A 1.5 mg/kg SC | MTRX1011A 3.5 mg/kg SC | MTRX1011A 5.0 mg/kg IV | |||||
|---|---|---|---|---|---|---|---|---|
| baseline | eight weeks | baseline | eight weeks | baseline | eight weeks | baseline | eight weeks | |
| ACR20, % patients | 14 | 8 | 33 | 25 | ||||
| ACR50, % patients | 0 | 0 | 25 | 0 | ||||
| ACR70, % patients | 0 | 0 | 8 | 0 | ||||
| DAS-CRP | 5.4 (4.3 to 6.6) | 4.4 (3.2 to 5.9) | 5.7 (4.1 to 6.7) | 5.6 (4.0 to 7.7) | 5.9 (3.7 to 6.8) | 4.6 (2.6 to 6.8) | 6.5 (4.2 to 8.0) | 5.5 (3.2 to 6.8) |
| CRP, mg/dL | 1.7 (0.03 to 4.0) | 1.1 (0.1 to 3.0) | 0.8 (0.02 to 2.3) | 1.1 (0.02 to 4.2) | 1.1 (0.02 to 7.7) | 1.7 (0.1 to 9.8) | 2.1 (0.1 to 8.2) | 1.1 (0.1 to 3.9) |
| ESR, mm/hour | 47 (15 to 120) | 36 (8 to 104) | 32 (8 to 60) | 30 (6 to 108) | 39 (0 to 78) | 34 (8 to 58) | 61 (26 to 110) | 51 (29 to 104) |
| SJC | 7 (0 to 16) | 7 (0 to 19) | 14 (2 to 30) | 18 (2 to 51) | 20 (7 to 52) | 8 (0 to 36) | 26 (3 to 59) | 17 (0 to 30) |
| TJC | 36 (10 to 53) | 25 (3 to 62) | 42 (12 to 65) | 37 (4 to 67) | 41 (8 to 68) | 18 (0 to 66) | 48 (22 to 65) | 30 (24 to 33) |
| VAS, | ||||||||
| Patient, pain | 60 (42 to 77) | 39 (19 to 57) | 57 (17 to 79) | 59 (10 to 89) | 62 (18 to 91) | 54 (14 to 89) | 78 (62 to 90) | 47 (20 to 67) |
| Patient, overall | 69 (54 to 94) | 43 (18 to 75) | 63 (17 to 98) | 58 (17 to 88) | 70 (40 to 93) | 56 (10 to 87) | 81 (60 to 100) | 52 (25 to 75) |
| VAS, Physician, global | 60 (26 to 78) | 44 (25 to 63) | 51 (21 to 80) | 52 (12 to 88) | 66 (35 to 100) | 51 (13 to 88) | 58 (45 to 76) | 52 (33 to 73) |
Data are expressed as group mean, with ranges depicted between parentheses. ACR, American College of Rheumatology; CRP, C-reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; IV, intravenous; SC, subcutaneous; SJC, swollen joint count; TJC, tender joint count; VAS, visual analog scale.